Navigation Links
Long-term NSAID use by hypertensive patients with CAD increases risk of adverse events
Date:7/13/2011

New York, NY, July 12, 2011 A study published in the July issue of The American Journal of Medicine, reports that among hypertensive patients with coronary artery disease, chronic self-reported use of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of adverse events during long-term follow-up. Long-term NSAIDs use is common for treatment of chronic pain.

Researchers from the Division of Cardiovascular Medicine, College of Medicine and the Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, found that after a mean of 2.7 years of follow-up, in hypertensive patients with coronary artery disease (average age of 65 years), chronic self-reported NSAID use was associated with a 47% increase in the occurrence of death, nonfatal myocardial infarction, or nonfatal stroke. This was due to a 90% increase in all-cause mortality (which persisted into extended follow-up of more than 5 years), a 126% increase in cardiovascular mortality, and a 66% increase in total myocardial infarctions. There was no significant difference in the occurrence of stroke.

"Among coronary artery disease patients with hypertension, chronic self-reported use of NSAIDs was associated with harmful outcomes, and this practice should be avoided where possible," commented Anthony A. Bavry, MD, MPH, Assistant Professor, Division of Cardiovascular Medicine, College of Medicine at the University of Florida, Gainesville. "This association did not appear to be due to elevated blood pressure because chronic NSAID users actually had slightly lower on-treatment blood pressure over a mean of 2.7 years of follow-up. Until further data are available, alternative modes of pain relief should be considered for these patients."

Currently, there is a paucity of data about possible harmful effects of chronic NSAIDs in patients with hypertension and coronary artery disease. This observational study was conducted within a large randomized trial that provided long-term blood pressure measures, target blood pressures, and standardized assessment of adverse cardiovascular outcomes.

Data were obtained from INVEST (The INternational VErapamil Trandolapril Study), a randomized trial conducted in 14 countries, originally designed to compared the effects of a calcium antagonist (verapamil SR)-based strategy with a beta-blocker (atenolol)-based strategy for hypertension among patients with stable coronary artery disease. In this study, there were 882 chronic NSAID users and 21,694 nonchronic NSAID users. Many of the previous analyses on this topic have been conducted from case-control studies.

Interestingly investigators did not find a difference in serious gastrointestinal bleeding events from chronic NSAID use, as might have been expected. While this was somewhat counterintuitive, chronic NSAID users likely started these medications before study enrollment, at which time major bleeding events could have occurred.


'/>"/>

Contact: Pamela Poppalardo
ajmmedia@elsevier.com
732-238-3628
Elsevier Health Sciences
Source:Eurekalert

Related medicine news :

1. Cuddling May Be Key to Long-Term Happy Relationship
2. Study shows long-term benefits of breast screening
3. Study: Long-term inhaled corticosteroid use increases fracture risk in lung disease patients
4. Chips, Fries, Soda Most to Blame for Long-Term Weight Gain
5. Angioplasty with stents may be safe in long-term for low-risk heart patients
6. Its not about the money for long-term care nurses
7. New study aims to improve long-term treatment for patients with bipolar disorder
8. Enlarged prostate: Study demonstrates immediate and long-term benefits of laser treatment
9. Antibody production gets confused during long-term spaceflight
10. Simple fitness test could predict long-term risk for heart attack, stroke in middle-aged people
11. High pregnancy weight gain can lead to long-term obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: